Trials / Completed
CompletedNCT05350787
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL
To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Relapsed and Refractory Acute B-cell Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with relapsed and refractory acute B-cell leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ThisCART19A | ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia |
Timeline
- Start date
- 2022-03-18
- Primary completion
- 2025-05-21
- Completion
- 2025-05-21
- First posted
- 2022-04-28
- Last updated
- 2026-02-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05350787. Inclusion in this directory is not an endorsement.